‘Platform-as-a-Service’ (PaaS) offers IT efficiencies especially for emerging biopharma
Just as biopharma companies are growing more comfortable with software-as-a-service (SaaS) for customer-relationship management, accounting and other IT functions, now it is being offered “IT in a box” to have a preconfigured, validated IT infrastructure through a managed services agreement (MSA). Such MSAs are an increasingly common feature of the IT industry, but the innovation here is to structure the MSA specifically for biopharma needs.
“We’ve been offering various types of managed services, such as handling corporate e-mail, disaster recovery and others for quite a while,” says John Biglin, CEO of Interphase Systems (Plymouth Meeting, PA). “We’ve realized that there is value in bundling all these capabilities as one offering, which we call Ready-IT BioPharma.”
Ready-IT is structured a la carte to meet various IT requirements in biopharma, including CRM, ERP, voice and data communications, disaster recovery and regulatory compliance. The company has also offered a tailored corrective-and-preventive-action (CAPA) managed service for handling FDA compliance issues. Interphase is most familiar with Microsoft-based enterprise tools, but some IT applications are defined by user requirements. Biglin says that although the service is most suitable for small to mid-size biopharma companies, Interphase has worked with several Big Pharma firms on specific IT applications. “Small to mid-size companies need to have industrial-strength IT infrastructures, but often don’t want to tie up capital or management resources in building their own systems,” he says.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.